<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2908210993
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Neulasta Onpro
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PEGFILGRASTIM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3531.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AMGEN MANUFACTURING LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AMGEN MANUFACTURING LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            KYOWA KIRIN LIMITED 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L03AA13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Neulasta contains the active substance pegfilgrastim. Pegfilgrastim is a protein produced by biotechnology in bacteria called <em>E. coli</em>. It belongs to a group of proteins called cytokines, and is very similar to a natural protein (granulocyte-colony stimulating factor) produced by your own body.</p><p>&nbsp;</p><p>Neulasta is used to reduce the duration of neutropenia (low white blood cell count) and the occurrence of febrile neutropenia (low white blood cell count with a fever) which can be caused by the use of cytotoxic chemotherapy (medicines that destroy rapidly growing cells). White blood cells are important as they help your body fight infection. These cells are very sensitive to the effects of chemotherapy which can cause the number of these cells in your body to decrease. If white blood cells fall to a low level there may not be enough left in the body to fight bacteria and you may have an increased risk of infection.</p><p>&nbsp;</p><p>Your doctor has given you Neulasta to encourage your bone marrow (part of the bone which makes blood cells) to produce more white blood cells that help your body fight infection.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Neulasta</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to pegfilgrastim, filgrastim, or any of the other ingredients of this medicine.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>&nbsp;</p><p>Talk to your doctor, pharmacist or nurse before using Neulasta:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience an allergic reaction including weakness, drop in blood pressure, difficulty breathing, swelling of the face (anaphylaxis), redness and flushing, skin rash and areas of the skin that itch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an allergy to latex. The needle cap on the pre-filled syringe contains a derivative of latex and may cause severe allergic reactions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an allergy to acrylic adhesives. The on‑body injector uses acrylic adhesive and may result in an allergic reaction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience a cough, fever and difficulty breathing. This can be a sign of Acute Respiratory Distress Syndrome (ARDS).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any of the following or combination of the following side effects:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness.</p><p>These could be symptoms of a condition called &ldquo;Capillary Leak Syndrome&rdquo; which causes blood to leak from the small blood vessels into your body. See section&nbsp;4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get left upper abdominal pain or pain at the tip of your shoulder. This may be a sign of a problem with your spleen (splenomegaly).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently had a serious lung infection (pneumonia), fluid in the lungs (pulmonary oedema), inflammation of the lungs (interstitial lung disease) or an abnormal chest x‑ray (lung infiltration).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are aware of any altered blood cell counts (e.g. increase in white blood cells or anaemia) or decreased blood platelet counts, which reduces the ability of your blood to clot (thrombocytopenia). Your doctor may want to monitor you more closely.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have sickle cell anaemia. Your doctor may monitor your condition more closely.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are a patient with breast cancer or lung cancer, Neulasta in combination with chemotherapy and/or radiation therapy may increase your risk of a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukaemia (AML). Symptoms may include tiredness, fever, and easy bruising or bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have sudden signs of allergy such as rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or trouble breathing these could be signs of a severe allergic reaction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have symptoms of inflammation of aorta (the large blood vessel which transports blood from the heart to the body), this has been reported rarely in cancer patients and healthy donors. The symptoms can include fever, abdominal pain, malaise, back pain and increased inflammatory markers. Tell your doctor if you experience those symptoms.</p><p>&nbsp;</p><p>Your doctor will check your blood and urine regularly as Neulasta can harm the tiny filters inside your kidneys (glomerulonephritis).</p><p>&nbsp;</p><p>Severe skin reactions (Stevens-Johnson syndrome) have been reported with the use of Neulasta. Stop using Neulasta and seek medical attention immediately if you notice any of the symptoms described in section 4.</p><p>&nbsp;</p><p>You should talk to your doctor about your risks of developing cancers of the blood. If you develop or are likely to develop cancers of the blood, you should not use Neulasta, unless instructed by your doctor.</p><p>&nbsp;</p><p><strong>Loss of response to pegfilgrastim</strong></p><p>&nbsp;</p><p>If you experience a loss of response or failure to maintain a response with pegfilgrastim treatment, your doctor will investigate the reasons why including whether you have developed antibodies which neutralise pegfilgrastim&rsquo;s activity.</p><p>&nbsp;</p><p>Other medicines and Neulasta</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine. Neulasta has not been tested in pregnant women. It is important to tell your doctor if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; think you may be pregnant; or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are planning to have a baby.</p><p>&nbsp;</p><p>Unless your doctor directs you otherwise, you must stop breast-feeding if you use Neulasta.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Neulasta has no or negligible effect on the ability to drive or use machines.</p><p>&nbsp;</p><p><strong>Neulasta </strong><strong>contains sorbitol (E420) and sodium acetate</strong></p><p><strong>&nbsp;</strong></p><p>This medicine contains 30 mg sorbitol in each pre-filled syringe which is equivalent to 50 mg/mL.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per 6 mg dose, that is to say essentially</p><p>&lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Neulasta is for use in adults aged&nbsp;18 and over.</p><p>&nbsp;</p><p>Always take Neulasta exactly as your doctor has told you. You should check with your doctor or pharmacist if you are unsure. The usual dose is one 6&nbsp;mg subcutaneous injection (injection under your skin) and it should be given at least 24&nbsp;hours after your last dose of chemotherapy at the end of each chemotherapy cycle.</p><p><strong>&nbsp;</strong></p><p><strong>Using Neulasta with the on-body injector</strong></p><p>&nbsp;</p><p>Your doctor may decide that it would be more convenient for you to use Neulasta with the on‑body injector. For further information on use with the on‑body injector, please read the instructions for use at the end of this leaflet.</p><p>&nbsp;</p><p>Check the instructions at the end of this leaflet and contact your healthcare provider if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; during the monitoring of your on‑body injector you are concerned that it is leaking; or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after the injection is complete you are concerned that you may not have received the full dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Please tell your doctor immediately if you have any of the following or combination of the following side effects:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness. These symptoms generally develop in a rapid fashion.</p><p>&nbsp;</p><p>These could be symptoms of an uncommon (may affect up to&nbsp;1 in 100&nbsp;people) condition called &ldquo;Capillary Leak Syndrome&rdquo; which causes blood to leak from the small blood vessels into your body and needs urgent medical attention.</p><p>&nbsp;</p><p><strong>Very common side effects </strong>(may affect more than&nbsp;1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone pain. Your doctor will tell you what you can take to ease the bone pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea and headaches.</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to&nbsp;1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, itchy red raised bumps (contact dermatitis/local skin reactions) have been seen with the on‑body injector.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain at the site of injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; application site reactions which may include redness, bleeding, bruising, pain and discomfort have been seen with the on‑body injector.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; general aches and pains in the joints and muscles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some changes may occur in your blood, but these will be detected by routine blood tests. Your white blood cell count may become high for a short period of time. Your platelet count may become low which might result in bruising.</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to&nbsp;1 in 100&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic-type reactions, including redness and flushing, skin rash, and raised areas of the skin that itch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious allergic reactions, including anaphylaxis (weakness, drop in blood pressure, difficulty breathing, swelling of the face).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased spleen size.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spleen rupture. Some cases of splenic rupture were fatal. It is important that you contact your doctor immediately if you experience pain in the upper left side of the abdomen or left shoulder pain since this may relate to a problem with your spleen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing problems. If you have a cough, fever and difficulty breathing please tell your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sweet&rsquo;s syndrome (plum-coloured, raised, painful lesions on the limbs and sometimes the face and neck with fever) has occurred but other factors may play a role.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cutaneous vasculitis (inflammation of the blood vessels in the skin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage to the tiny filters inside your kidneys (glomerulonephritis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness at the site of injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing up blood (haemoptysis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood disorders (myelodysplastic syndrome [MDS] or acute myeloid leukaemia [AML]).</p><p>&nbsp;</p><p><strong>Rare side effects </strong>(may affect up to&nbsp;1 in 1000&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of aorta (the large blood vessel which transports blood from the heart to the body), see section&nbsp;2.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding from the lung (pulmonary haemorrhage).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;Stevens-Johnson syndrome, which can appear as reddish target-like or circular patches often</p><p>with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes</p><p>and can be preceded by fever and flu-like symptoms. Stop using Neulasta if you develop these</p><p>symptoms and contact your doctor or seek medical attention immediately. See also section 2.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the syringe label after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C).</p><p>&nbsp;</p><p>The syringe for use with the on‑body injector must either be used within 12&nbsp;hours after it has reached room temperature (not above&nbsp;30&deg;C) or disposed of.</p><p>&nbsp;</p><p>Do not freeze. Neulasta &nbsp;may be used if it is accidentally frozen for a single period of less than 24&nbsp;hours.</p><p>&nbsp;</p><p>Keep the container in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine if you notice it is cloudy or there are particles in it.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Neulasta contains</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is pegfilgrastim. Each pre-filled syringe contains 6&nbsp;mg of pegfilgrastim in 0.6&nbsp;mL of solution.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sodium acetate, sorbitol (E420), polysorbate&nbsp;20 and water for injections. See section&nbsp;2.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
What Neulasta Onpro looks like and contents of the pack

Neulasta is a clear, colourless solution for injection in a pre-filled syringe (6 mg/0.6 mL).

Each pack contains 1 glass pre-filled syringe with an attached stainless steel needle and needle cap.

One pre-filled syringe with blister wrapping and with an on body injector.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Kyowa Kirin Limited</p><p>Galabank Business Park</p><p>Galashiels</p><p>TD1 1QH</p><p>UK</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Amgen Manufacturing Limited</p><p>State Road 31</p><p>Kilometer 24.6</p><p>Juncos 00777-4060</p><p>Puerto Rico</p><p>USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in November 2020.

To report any side effect(s):
The National Pharmacovigilance and Drug Safety Center (NPC)
o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
o Fax: +966-11-205-7662
o Toll-free: 8002490000
	o E-mail: npc.drug@sfda.gov.sa
	o Website: www.sfda.gov.sa/npc


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p dir="RTL">يحتوي نيولاستا على المادة الفعالة بيغفيلجراستيم، إن بيغفيلجراستيم هو بروتين يُنتج من خلال تكنولوجيا حيوية ببكتيريا اسمها <em>الإشريكية القولونية</em>. وتنتمي هذه المادة إلى فئة من البروتينات اسمها السيتوكينات، وهي شديدة الشبه ببروتين طبيعي (عامل تحفيز مستعمرات الخلايا المحببة) الذي ينتجه جسمك.</p><p>&nbsp;</p><p dir="RTL">يستخدم نيولاستا لتقليل مدة الإصابة بقلة العَدِلات (انخفاض عدد خلايا الدم البيضاء) وحدوث قلة العدلات الحموية (انخفاض عدد خلايا الدم البيضاء المصحوب بحمى) الذي قد يسببه استخدام العلاج الكيميائي السام للخلايا (الأدوية التي تُدمر الخلايا التي تتكاثر بسرعة). وخلايا الدم البيضاء مهمة لصحتك لأنها تساعد جسمك على مكافحة العدوى، ولكن هذه الخلايا حساسة للغاية تجاه آثار العلاج الكيميائي التي قد تخفض عدد هذه الخلايا في جسمك. وإذا وصل عدد خلايا الدم البيضاء إلى مستوى منخفض، فقد لا يكفي العدد المتبقي في الجسم لمكافحة البكتيريا وقد تزداد احتمالات تعرضك لخطر الإصابة بالعدوى.</p><p>&nbsp;</p><p dir="RTL">وقد وصف لك طبيبك دواء نيولاستا لتحفيز نخاع العظم في جسمك (جزء من العظم مسؤول عن إنتاج خلايا الدم) على إنتاج المزيد من خلايا الدم البيضاء التي تساعد جسمك على مكافحة العدوى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">لا تستخدم نيولاستا</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه بيغفيلجراستيم أو فيلجراستيم أو أيٍ من المكونات الأخرى لهذا الدواء.</p><p>&nbsp;</p><p dir="RTL">التحذيرات والاحتياطات</p><p>&nbsp;</p><p dir="RTL">استشر طبيبك أو الصيدلي أو الممرضة قبل استخدام نيولاستا:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;في حال إصابتك برد فعل تحسسي يشمل الإحساس بالضعف وانخفاض ضغط الدم وصعوبة التنفس وتورم الوجه (التأق) والاحمرار والبيغ والطفح الجلدي وحكة في الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;في حال إصابتك بحساسية من مادة اللاتكس. فغطاء الإبرة الموجود على الحقنة المملوءة مسبقًا على مادة مشتقة من اللاتكس وقد يتسبب في تفاعلات حساسية &nbsp;شديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;في حال إصابتك بحساسية من مواد الأكريليك اللاصقة. فالمحقن المثبت على الجسم يستخدم مادة أكريليك لاصقة وقد ينتج عنه تفاعلات حساسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;في حال إصابتك بسعال وحمى وصعوبة في التنفس. فقد تكون هذه علامة على الإصابة بمتلازمة الضائقة التنفسية الحادة (ARDS).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;في حال الإصابة بواحد أو أكثر من الآثار الجانبية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أو انتفاخ، اللذان قد يصاحبهما قلة عدد مرات التبول وصعوبة التنفس وتورم البطن والشعور بالامتلاء وشعور عام بالتعب.</p><p dir="RTL">قد تكون هذه أعراض حالة تُسمَّى &quot;متلازمة التسرب الشعيري&quot; والتي تسبب تسرب الدم من الأوعية الدموية الصغيرة إلى جسمك. انظر القسم ٤.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;في حال الإصابة بألم في أعلى يسار البطن أو بألم في طرف كتفك. فقد تكون هذه علامة على مشكلة بالطحال (تضخم الطحال).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;في حال إصابتك مؤخرًا بعدوى خطيرة بالرئة (التهاب رئوي) أو تجمع للسوائل في الرئتين (الوذمة الرئوية) أو بالتهاب الرئتين (داء الرئة الخلالي) أو خضوعك لفحص الصدر بالأشعة السينية وكشف عن نتائج غير طبيعية (الارتشاح الرئوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال معرفتك بإصابتك بأي تغير في عدد خلايا الدم (مثل زيادة عدد خلايا الدم البيضاء أو فقر الدم) أو انخفاض عدد الصفائح الدموية، التي تقلل من قدرة دمك على التخثر (قلة الصفائح الدموية). فقد يرغب طبيبك في متابعتك أكثرعن قرب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال إصابتك بفقر الدم المنجلي. فقد يتابع طبيبك حالتك أكثر عن قرب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مريضًا بسرطان الثدي أو الرئة، قد يزيد استخدام &nbsp;نيولاستا بتوليفة مع العلاج الكيميائي و/أو العلاج الإشعاعي من خطر تعرضك للإصابة بحالة في الدم سابقة للتسرطن تعرف بمتلازمة خلل التنسج النخاعي MDS أو بنوع من سرطان الدم اسمه ابيضاض الدم (اللوكيميا) النخاعي الحاد&nbsp; AML. وقد تشمل الأعراض الإعياء والحمى وحدوث كدمات أو نزف لأبسط الأسباب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;في حال إصابتك بعلامات حساسية (تحسس) مفاجئة مثل الطفح الجلدي أو الحكة أو شرى على الجلد أو تورم في الوجه أو الشفتين أو اللسان أو أجزاء أخرى من الجسم أو ضيق في التنفس أو صفير أو صعوبة في التنفس؛ فقد تكون هذه الأعراض علامات على رد فعل تحسسي شديد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كان لديك أعراض التهاب الشريان الأورطي. في أحوال نادرة تم الإبلاغ عن التهاب الشريان الأورطي (الشريان الكبير الذي ينقل الدم من القلب إلى الجسم) بين مرضى السرطان والمتبرعين الأصحاء. ويمكن أن تتضمن الأعراض الحمى، وألم البطن، والتوعك، وألم الظهر، وزيادة معدلات دلائل الالتهاب. أخبر طبيبك إذا أصبت بأي من هذه الأعراض.</p><p>&nbsp;</p><p dir="RTL">سوف يجري لك طبيبك تحليلات دم وبول بانتظام لأن نيولاستا قد يضر بالمرشحات الصغيرة داخل الكليتين (التهاب كبيبات الكلى).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن ردود فعل جلدية شديدة (متلازمة ستيفنز-جونسون) عند استخدام &nbsp;نيولاستا. توقف عن استخدام نيولاستا واطلب الرعاية الطبية فورًا إذا لاحظت أيًا من الأعراض الموضحة في القسم ٤</p><p>&nbsp;</p><p dir="RTL">ينبغي عليك مناقشة طبيبك بشأن أخطار إصابتك بسرطانات الدم. إذا أصبت بسرطانات الدم أو كان من المحتمل أن تصاب بها، فيجب ألا تستخدم نيولاستا إلا إذا طلب منك طبيبك ذلك.</p><p>&nbsp;</p><p dir="RTL"><strong>فقدان الاستجابة للعلاج ببيغفيلجراستيم</strong></p><p>&nbsp;</p><p dir="RTL">إذا توقف جسمك عن الاستجابة للعلاج ببيغفيلجراستيم أو لم يعد قادرًا على الحفاظ على الاستجابة له، فسوف يبحث طبيبك أسباب ذلك، بما في ذلك احتمال أن يكون جسمك قد أنتج أجسامًا مضادة تُبطل مفعول بيغفيلجراستيم.</p><p>&nbsp;</p><p dir="RTL">الأدوية الأخرى ونيولاستا</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي، إذا كنت تتناول أو تناولت مؤخرا، أو قد تتناول أي أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL">الحمل والرضاعة الطبيعية</p><p>&nbsp;</p><p dir="RTL">احرصي على استشارة طبيبك أو الصيدلي قبل تناول أي دواء. لم يتم اختبار نيولاستا في النساء الحوامل، ولهذا فمن المهم أن تخبري طبيبك إذا كنتِ:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاملا؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعتقدين أنكِ قد تكونين حاملا؛ أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخططين للإنجاب.</p><p>&nbsp;</p><p dir="RTL">يجب عليكِ إيقاف الرضاعة الطبيعية إذا كنتِ تستخدمين نيولاستا، إلا إذا طلب منك طبيبك غير ذلك.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p>&nbsp;</p><p dir="RTL">نيولاستا له تأثير ضئيل أو منعدم على القدرة على القيادة واستخدام الآلات .</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي نيولاستا على السوربيتول (E٤٢٠) وأسيتات الصوديوم</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا الدواء على ٣٠ مجم من السوربيتول في كل محقنة معبأة مسبقًا وهو ما يعادل ٥٠ مجم/ملليلتر.</p><p dir="RTL">يحتوي هذا الدواء على أقل من ١&nbsp;مليمول من الصوديوم(<strong>٢</strong><strong>۳</strong>&nbsp;مجم) &nbsp;&nbsp;بكل جرعة قدرها ٦&nbsp;مجم، أيْ أنه أساسًا &quot;خالٍ من الصوديوم&quot;.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">نيولاستا مخصص للاستخدام لدى البالغين من العمر ١۸ عاما فما أكثر.</p><p>&nbsp;</p><p dir="RTL">احرص دائمًا على استخدام نيولاستا كما أوصاك طبيبك بالضبط. يجب عليك استشارة طبيبك أو الصيدلي إذا لم تكن متأكدًا. الجرعة المعتادة هي حقنة تحت الجلد ٦&nbsp;مجم (تُحقن تحت الجلد) ويجب أن تعطى بعد ٢٤&nbsp;ساعة على الأقل من آخر جرعة من العلاج الكيميائي في نهاية كل دورة علاج كيميائي.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>استخدام نيولاستا عن طريق المحقن المثبت </strong><strong>على </strong><strong>الجسم</strong></p><p>&nbsp;</p><p dir="RTL">قد يقرر طبيبك أن استخدام نيولاستا عن طريق المحقن المثبت على الجسم سيكون أكثر راحة لك. لمزيد من المعلومات حول الاستخدام عن طريق المحقن المثبت على الجسم، يُرجى قراءة تعليمات الاستخدام في نهاية هذه النشرة.</p><p>&nbsp;</p><p dir="RTL">راجع التعليمات في نهاية هذه النشرة واتصل بمقدم الرعاية الصحية في &nbsp;حال:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء ملاحظتك للمحقن المثبت على الجسم &nbsp;قلقت من &nbsp;حدوث تسريب منه؛ أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلقت بعد اكتمال الحقن أنك ربما لم تحصل على الجرعة كاملةً.</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL">يرجى إخبار الطبيب فورًا إذا أُصِبت بأثر واحد أو أكثر من الآثار الجانبية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أو انتفاخ، واللذان قد يصاحبهما قلة عدد مرات التبول وصعوبة التنفس وتورم البطن والشعور بالامتلاء وشعور عام بالتعب. عمومًا، تظهر هذه الأعراض سريعًا،</p><p>&nbsp;</p><p dir="RTL">وقد تكون أعراضًا لحالة غير شائعة (قد تصيب ما يصل إلى شخص واحد من كل ١٠٠&nbsp;شخص) اسمها &quot;متلازمة التسرب الشعيري&quot; والتي تسبب تسرب الدم من الأوعية الدموية الصغيرة إلى جسمك وتحتاج إلى عناية طبية عاجلة.</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًا </strong>(قد تُصيب أكثر من شخص واحد من بين كل ١٠&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العظام. سيُخبرك طبيبك بالأدوية التي يمكنك تناولها لتخفيف آلام العظام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان والصداع.</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة </strong>(قد تُصيب ما لا يزيد عن شخص واحد من بين كل ١٠&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود حالات طفح جلدي، ونتوءات حمراء بارزة تثير الحكة (التهاب الجلد التلامسي/ردود فعل جلدية موضعية) عند استخدام المحقن المثبت على الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في مكان الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود ردود فعل في مكان المحقن والتي قد تشمل احمرار، ونزيف، وكدمات، وألم وعدم ارتياح عند استخدام المحقن المثبت على الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوجاع وآلام عامة في المفاصل والعضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث بعض التغييرات في دمك، ولكنها سوف تُكتشف في تحليلات الدم الدورية. فقد يرتفع عدد خلايا الدم البيضاء لديك لفترة زمنية قصيرة. وقد ينخفض عدد الصفائح الدموية مما قد يسبب كدمات.</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة </strong>(قد تُصيب ما لا يزيد عن شخص واحد من بين كل ١٠٠&nbsp;شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية بما في ذلك الاحمرار والبيغ والطفح الجلدي وأجزاء مرتفعة بالجلد تشعر بحكة بها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية خطيرة، بما في ذلك التأق (إحساس بالضعف وانخفاض ضغط الدم وصعوبة التنفس وتورم الوجه).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حجم الطحال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزق الطحال. بعض حالات تمزق الطحال التي حدثت كانت مميتة. من المهم الاتصال بطبيبك على الفور إذا تعرضت لألم في أعلى البطن من جهة اليسار أو ألم في كتفك الأيسر لأن هذا الألم قد يكون له علاقة بمشكلة في طحالك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التنفس. إذا كنت مصابًا بسعال وحمى وصعوبة في التنفس، فيُرجى إخبار طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم رصد حالات لمتلازمة سويت (آفات برقوقية اللون بارزة ومؤلمة بالأطراف، وتظهر أحيانًا في الوجه والعنق، مصحوبة بحمى)، ولكن هناك عوامل أخرى ربما يكون لها دور في الإصابة بها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية الجلدية (التهاب الأوعية الدموية في الجلد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرض المرشحات الصغيرة داخل الكلى لتلف (التهاب كبيبات الكلى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار في مكان الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال مصحوب بدم (نفث الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اضطرابات الدم </strong>(<strong>خلل التنسج النخاعي</strong>&nbsp; MDS أو ابيضاض الدم (اللوكيميا) النخاعي الحاد AML<strong> )</strong></p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة </strong>(قد تُصيب ما لا يزيد عن شخص واحد من بين كل ١٠٠٠&nbsp;شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الشريان الأورطي (الوعاء الدموي الكبير الذي ينقل الدم من القلب إلى بقية الجسم)، انظر القسم ٢.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الرئة (نزيف رئوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستيفنز-جونسون والتي تظهر على هيئة بقع مائلة للون الأحمر مثل علامات تصويب الأهداف أو بقع دائرية، وغالبًا ما تصحبها بثور في المنتصف في منطقة الجذع، وتقشر الجلد، وقروح في الفم والحلق والأنف والأعضاء التناسلية والعينين وقد يسبقها حمى أو أعراض تشبه أعراض الأنفلونزا. توقف عن استخدام &nbsp;نيولاستا إذا أصبت بهذه الأعراض واتصل بطبيبك أو اطلب الرعاية الطبية فورًا. انظر أيضًا القسم ٢</p><p dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>&nbsp;</p><p dir="RTL">إذا أصبت بأي آثار جانبية، فاستشر طبيبك أو الصيدلي أو الممرضة؛ بما في ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً (انظر التفاصيل أدناه). وبالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدا عن أعين الأطفال ومتناول أيديهم.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العبوة الكرتونية وعلى ملصق الحقنة بعد الاختصار &quot;EXP&quot; (تاريخ انتهاء الصلاحية)، علمًا بأن هذا التاريخ يُشير إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">يُحفظ في الثلاجة (٢&deg;م - ۸&deg;م).</p><p>&nbsp;</p><p dir="RTL">يجب استخدام الحقنة المخصصة للاستخدام مع المحقن المثبت على الجسم في غضون ١٢&nbsp;ساعة بعد وصولها لدرجة حرارة الغرفة (بما لا يزيد عن ۳٠&deg; م) أو التخلص منها.</p><p>&nbsp;</p><p dir="RTL">لا تجمّد هذا الدواء. ويمكن استخدام نيولاستا في حال تجميده بطريق الخطأ مرة واحدة لمدة أقل من ٢٤&nbsp;ساعة.</p><p>&nbsp;</p><p dir="RTL">احفظ العبوة داخل العلبة الكرتونية الخارجية لحمايتها من الضوء.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أنه معكر أو يحتوي على جسيمات.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية بإلقائها في مياه الصرف الصحي أو في النفايات المنزلية. اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستخدمها؛ فاتباع هذه الطريقة يساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكونات نيولاستا</strong></p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي بيغفيلجراستيم. وتحتوي كل عبوة على الحقنه المملوءة مسبقًا على ٦&nbsp;مجم من بيغفيلجراستيم في ٠٫٦&nbsp;مل من المحلول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي أسيتات الصوديوم، والسوربيتول (E٤٢٠)، وبوليسوربات&nbsp;٢٠ وماء للحقن. انظر القسم ٢.</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">نيولاستا هو محلول صافٍ عديم اللون للحقن في حقنة مملوءة مسبقًا (٦&nbsp;مجم/٠٫٦&nbsp;مل).</p><p>&nbsp;</p><p dir="RTL">تحتوي كل عبوة على حقنة زجاجية واحدة مملوءة مسبقًا، مثبت بها إبرة من الفولاذ المقاوم للصدأ وغطاء للإبرة.</p><p>&nbsp;</p><p dir="RTL">حقنة واحدة مملوءة مسبقًا في غلاف بلاستيكي مع المحقن الذي يُثبت على الجسم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>صاحب ترخيص التسويق</strong></p><p dir="RTL">Kyowa Kirin Limited</p><p dir="RTL">Galabank Business Park</p><p dir="RTL">Galashiels</p><p dir="RTL">TD1 1QH</p><p dir="RTL">المملكة المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المصنع</strong></p><p dir="RTL"><strong>&nbsp;</strong>Amgen Manufacturing Limited</p><p dir="RTL">State Road 31</p><p dir="RTL">Kilometer 24.6</p><p dir="RTL">Juncos 00777-4060</p><p dir="RTL">Puerto Rico</p><p dir="RTL">الولايات المتحدة الأمريكية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
تمت آخر مراجعة لهذه النشرة في نوفمبر ٢٠ ٢٠

للإبلاغ عن الأعراض الجانبية:
المركز الوطني للتيقظ والسلامة الدوائية
o	هاتف: ٠٠٩٦٦١١٢٠٣٨٢٢٢
o	تحويلة: ٢۳١۷-٢۳٥٦-٢۳٥۳-٢۳٥٤-٢۳۳٤-٢۳٤٠
o	فاكس: ٠٠٩٦٦١١٢٠٥٧٦٦٢
o	الهاتف المجاني: ۸٠٠٢٤۹٠٠٠٠
o	بريد الكتروني: npc.drug@sfda.gov.sa 
o	موقع الكتروني: www.sfda.gov.sa/npc 



        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Neulastim  6 mg solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each pre-filled syringe contains 6 mg of pegfilgrastim* in 0.6 mL solution for injection. The concentration is 10 mg/mL based on protein only**.

* Produced in Escherichia coli cells by recombinant DNA technology followed by conjugation with polyethylene glycol (PEG).
** The concentration is 20 mg/mL if the PEG moiety is included.

The potency of this product should not be compared to the potency of another pegylated or non-pegylated protein of the same therapeutic class. For more information, see section 5.1.

Excipients with known effect
Each pre-filled syringe contains 30 mg sorbitol (E420) (see section 4.4). For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).
Solution for injection (injection) with on-body injector (Onpro kit). Clear, colourless solution for injection.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Neulastim &nbsp;therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Posology</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">One 6 mg dose (a single pre-filled syringe) of Neulastim &nbsp;is recommended for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Special populations</u></p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">The safety and efficacy of Neulastim &nbsp;in children has not yet been established. Currently available data are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Patients with renal impairment</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">No dose change is recommended in patients with renal impairment, including those with end-stage renal disease.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Neulastim &nbsp;is injected subcutaneously via:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a pre-filled syringe for manual administration; or</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a pre-filled syringe with on-body injector for automatic administration.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Neulastim &nbsp;6 mg solution for injection in pre-filled syringe</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">The manually administered injections should be given into the thigh, abdomen or upper arm.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Neulastim &nbsp;6 mg solution for injection in pre-filled syringe with on-body injector</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">The on-body injector must be filled using the co-packed pre-filled syringe. The on-body injector should be applied to intact, non-irritated skin on the back of the arm or abdomen. The back of the arm may only be used if there is a caregiver available to monitor the status of the on-body injector.</p><p dir="ltr">Approximately 27 hours after the on-body injector is applied to the patient&rsquo;s skin, Neulastim &nbsp;will be delivered over approximately 45 minutes. Once filled, the on-body injector should be used for immediate application and can be applied on the same day as the administration of cytotoxic chemotherapy, as long as application is timed to ensure the on-body injector delivers Neulastim &nbsp;at least 24 hours after administration of cytotoxic chemotherapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The on-body injector must only be used with the co-packed pre-filled syringe. The co-packed</p><p dir="ltr">pre-filled syringe contains additional solution to compensate for residual liquid retained in the on-body injector after delivery. If the pre-filled syringe co-packed with the on-body injector is used for manually administering a subcutaneous injection, the patient will receive more than the recommended dose. If the pre-filled syringe for manual administration is used with the on-body injector, the patient may receive less than the recommended dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For instructions on handling of the medicinal product before administration, see section 6.6.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substance or to any of the excipients

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Traceability</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">In order to improve the traceability of granulocyte-colony stimulating factors (G-CSFs), the trade name of the administered product should be clearly recorded in the patient file.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Limited clinical data suggest a comparable effect on time to recovery of severe neutropenia for pegfilgrastim to filgrastim in patients with <em>de novo </em>acute myeloid leukaemia (AML) (see section 5.1). However, the long-term effects of pegfilgrastim have not been established in AML; therefore, it should be used with caution in this patient population.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Granulocyte-colony stimulating factor can promote growth of myeloid cells <em>in vitro </em>and similar effects may be seen on some non-myeloid cells <em>in vitro</em>.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety and efficacy of pegfilgrastim have not been investigated in patients with myelodysplastic syndrome, chronic myelogenous leukaemia, and in patients with secondary AML; therefore, it should not be used in such patients. Particular care should be taken to distinguish the diagnosis of blast transformation of chronic myeloid leukaemia from AML.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety and efficacy of pegfilgrastim administration in <em>de novo </em>AML patients aged &lt; 55 years with cytogenetics t(15;17) have not been established.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety and efficacy of pegfilgrastim have not been investigated in patients receiving high dose chemotherapy. This medicinal product should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pulmonary adverse events</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Pulmonary adverse reactions, in particular interstitial pneumonia, have been reported after G-CSF administration. Patients with a recent history of pulmonary infiltrates or pneumonia may be at higher risk (see section 4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The onset of pulmonary signs such as cough, fever, and dyspnoea in association with radiological signs of pulmonary infiltrates, and deterioration in pulmonary function along with increased neutrophil count may be preliminary signs of Acute Respiratory Distress Syndrome (ARDS). In such circumstances pegfilgrastim should be discontinued at the discretion of the physician and the appropriate treatment given (see section 4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Glomerulonephritis</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Glomerulonephritis has been reported in patients receiving filgrastim and pegfilgrastim. Generally, events of glomerulonephritis resolved after dose reduction or withdrawal of filgrastim and pegfilgrastim. Urinalysis monitoring is recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Capillary leak syndrome</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Capillary leak syndrome has been reported after granulocyte-colony stimulating factor administration and is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care (see section 4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Splenomegaly and splenic rupture</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Generally asymptomatic cases of splenomegaly and cases of splenic rupture, including some fatal cases, have been reported following administration of pegfilgrastim (see section 4.8). Therefore, spleen size should be carefully monitored (e.g. clinical examination, ultrasound). A diagnosis of splenic rupture should be considered in patients reporting left upper abdominal pain or shoulder tip pain.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Thrombocytopenia and anaemia</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with pegfilgrastim alone does not preclude thrombocytopenia and anaemia because full dose myelosuppressive chemotherapy is maintained on the prescribed schedule. Regular monitoring of platelet count and haematocrit is recommended. Special care should be taken when administering single or combination chemotherapeutic agents which are known to cause severe thrombocytopenia.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Medication error as a result of device failure</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">There is a risk of medication error, particularly a partial or missed dose of pegfilgrastim, in the event of a device failure or malfunction with the on-body injector. In the event of a partial or missed dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered. The healthcare professional must ensure the patient receives appropriate training about the on-body injector and understands that if they suspect a device failure or malfunction the patient must immediately inform a healthcare professional as they may need a replacement dose. Comprehensive instructions for use for healthcare professionals and patients are given in the package leaflet. The patient should also be given the Patient Alert Card.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Sickle cell anaemia</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Sickle cell crises have been associated with the use of pegfilgrastim in patients with sickle cell trait or sickle cell disease (see section 4.8). Therefore, physicians should use caution when prescribing pegfilgrastim in patients with sickle cell trait or sickle cell disease, should monitor appropriate clinical parameters and laboratory status and be attentive to the possible association of this medicine with splenic enlargement and vaso-occlusive crisis.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Leukocytosis</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">White blood cell (WBC) counts of 100 x 10<sup>9</sup>/L or greater have been observed in less than 1% of patients receiving pegfilgrastim. No adverse events directly attributable to this degree of leukocytosis have been reported. Such elevation in white blood cells is transient, typically seen 24 to 48 hours after administration and is consistent with the pharmacodynamic effects of this medicine. Consistent with the clinical effects and the potential for leukocytosis, a WBC count should be performed at regular intervals during therapy. If leukocyte counts exceed 50 x 10<sup>9</sup>/L after the expected nadir, this medicine should be discontinued immediately.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Hypersensitivity</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Hypersensitivity, including anaphylactic reactions, occurring on initial or subsequent treatment have been reported in patients treated with pegfilgrastim. Permanently discontinue pegfilgrastim in patients with clinically significant hypersensitivity. Do not administer pegfilgrastim to patients with a history of hypersensitivity to pegfilgrastim or filgrastim. If a serious allergic reaction occurs, appropriate therapy should be administered, with close patient follow-up over several days.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Immunogenicity</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">As with all therapeutic proteins, there is a potential for immunogenicity. Rates of generation of antibodies against pegfilgrastim is generally low. Binding antibodies do occur as expected with all biologics; however, they have not been associated with neutralising activity at present.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Aortitis</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Aortitis has been reported after G-CSF administration in healthy subjects and in cancer patients. The symptoms experienced included fever, abdominal pain, malaise, back pain and increased inflammatory markers (e.g. c-reactive protein and white blood cell count). In most cases aortitis was diagnosed by CT scan and generally resolved after withdrawal of GCSF. See also section 4.8.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Other warnings</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety and efficacy of Neulastim &nbsp;for the mobilisation of blood progenitor cells in patients or healthy donors has not been adequately evaluated.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The needle cap of the pre-filled syringe contains dry natural rubber (a derivative of latex), which may cause allergic reactions.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The on-body injector uses an acrylic adhesive. For patients who have reactions to acrylic adhesives, use of this product may result in an allergic reaction.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Increased haematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone-imaging findings. This should be considered when interpreting bone-imaging results.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Neulastim &nbsp;contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">This medicine contains less than 1 mmol (23 mg) sodium per 6 mg dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Due to the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy&sbquo; pegfilgrastim should be administered at least 24 hours after administration of cytotoxic chemotherapy. In clinical trials, Neulastim &nbsp;has been safely administered 14 days before chemotherapy. Concomitant use of Neulastim &nbsp;with any chemotherapy agent has not been evaluated in patients. In animal models concomitant administration of Neulastim &nbsp;and 5-fluorouracil (5-FU) or other antimetabolites has been shown to potentiate myelosuppression.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Possible interactions with other haematopoietic growth factors and cytokines have not been specifically investigated in clinical trials.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The potential for interaction with lithium, which also promotes the release of neutrophils, has not been specifically investigated. There is no evidence that such an interaction would be harmful.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety and efficacy of Neulastim &nbsp;have not been evaluated in patients receiving chemotherapy associated with delayed myelosuppression e.g. nitrosoureas.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Specific interaction or metabolism studies have not been performed, however, clinical trials have not indicated an interaction of Neulastim &nbsp;with any other medicinal products.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">There are no or limited amount of data from the use of pegfilgrastim in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). pegfilgrastim is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Breast-feeding</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">There is insufficient information on the excretion of pegfilgrastim/metabolites in human milk, a risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue</p><p dir="ltr">breast-feeding or to discontinue/abstain from pegfilgrastim therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Pegfilgrastim did not affect reproductive performance or fertility in male or female rats at cumulative weekly doses approximately 6 to 9 times higher than the recommended human dose (based on body surface area) (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pegfilgrastim has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><u>Summary of the safety profile</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The most frequently reported adverse reactions were bone pain (very common [&ge; 1/10]) and musculoskeletal pain (common [&ge; 1/100 to &lt; 1/10]). Bone pain was generally of mild to moderate severity, transient and could be controlled in most patients with standard analgesics.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Hypersensitivity-type reactions, including skin rash, urticaria, angioedema, dyspnoea, erythaema, flushing, and hypotension occurred on initial or subsequent treatment with pegfilgrastim (uncommon [&ge; 1/1,000 to &lt; 1/100]). Serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim (uncommon) (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Capillary Leak Syndrome, which can be life-threatening if treatment is delayed, has been reported as uncommon (&ge; 1/1,000 to &lt; 1/100) in cancer patients undergoing chemotherapy following administration of granulocyte-colony stimulating factors; see section 4.4 and section &ldquo;Description of selected adverse reactions&rdquo; below.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Splenomegaly, generally asymptomatic, is uncommon.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Splenic rupture including some fatal cases is uncommonly reported following administration of pegfilgrastim (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Uncommon pulmonary adverse reactions including interstitial pneumonia, pulmonary oedema, pulmonary infiltrates and pulmonary fibrosis have been reported. Uncommonly, cases have resulted in respiratory failure or ARDS, which may be fatal (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Isolated cases of sickle cell crises have been reported in patients with sickle cell trait or sickle cell disease (uncommon in sickle cell patients) (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Tabulated summary of adverse reactions</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The data in the table below describe adverse reactions reported from clinical trials and spontaneous reporting. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common (&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge; 1/100 to &lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge; 1/1,000 to</strong></p><p><strong>&lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge; 1/10,000</strong></p><p><strong>to</strong></p><p><strong>&lt; 1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare (&lt; 1/10,000)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia1 Leukocytosis1</p></td><td style="vertical-align:top"><p>Sickle cell crisis2; Splenomegaly2; Splenic rupture2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p><p>reactions; Anaphylaxis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Elevations in uric acid</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Capillary leak syndrome1</p></td><td style="vertical-align:top"><p>Aortitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common (&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge; 1/100 to &lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge; 1/1,000 to</strong></p><p><strong>&lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge; 1/10,000</strong></p><p><strong>to</strong></p><p><strong>&lt; 1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare (&lt; 1/10,000)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute Respiratory Distress Syndrome2; Pulmonary adverse reactions (interstitial pneumonia, pulmonary oedema, pulmonary infiltrates and pulmonary fibrosis)</p><p>Haemoptysis</p></td><td style="vertical-align:top"><p>Pulmonary haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Nausea1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dermatitis contact1</p></td><td style="vertical-align:top"><p>Sweet&rsquo;s syndrome (acute febrile dermatosis)1,2</p><p>Cutaneous vasculitis1,2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Bone pain</p></td><td style="vertical-align:top"><p>Musculoskeletal pain (myalgia, arthralgia, pain in extremity, back pain, musculoskeletal pain, neck pain)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Glomerulonephritis2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administrative site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Injection site pain1 Application site reactions1</p><p>Non-cardiac chest pain</p></td><td style="vertical-align:top"><p>Injection site reactions2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Elevations in lactate dehydrogenase and alkaline phosphatase1; Transient elevations in LFTs for ALT or AST1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">1 See section &ldquo;Description of selected adverse reactions&rdquo; below.</p><p dir="ltr">2 This adverse reaction was identified through post-marketing surveillance but not observed in randomised, controlled clinical trials in adults. The frequency category was estimated from a statistical calculation based upon 1,576 patients receiving Neulastim &nbsp;in nine randomised clinical trials.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Description of selected adverse reactions</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Uncommon cases of Sweet&rsquo;s syndrome have been reported, although in some cases underlying haematological malignancies may play a role.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Uncommon events of cutaneous vasculitis have been reported in patients treated with pegfilgrastim. The mechanism of vasculitis in patients receiving pegfilgrastim is unknown.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Injection site reactions, including injection site erythaema (uncommon) as well as injection site pain (common) have occurred on initial or subsequent treatment with pegfilgrastim.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Application site reactions (including events such as haemorrhage, pain, discomfort, bruise, and erythaema) have been reported with the use of the on-body injector.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Contact dermatitis and local skin reactions such as rash, pruritus, and urticaria have been reported with the use of the on-body injector, possibly indicating a hypersensitivity reaction to the adhesive.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Common cases of leukocytosis (White Blood Count [WBC] &gt; 100 x 10<sup>9</sup>/L) have been reported (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Reversible, mild to moderate elevations in uric acid and alkaline phosphatase, with no associated clinical effects, were uncommon; reversible, mild to moderate elevations in lactate dehydrogenase, with no associated clinical effects, were uncommon in patients receiving Neulastim &nbsp;following cytotoxic chemotherapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Nausea and headaches were very commonly observed in patients receiving chemotherapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Uncommon elevations in liver function tests (LFTs) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), have been observed in patients after receiving pegfilgrastim following cytotoxic chemotherapy. These elevations are transient and return to baseline.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Common cases of thrombocytopenia have been reported.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Cases of capillary leak syndrome have been reported in the post-marketing setting with granulocyte- colony stimulating factor use. These have generally occurred in patients with advanced malignant diseases, sepsis, taking multiple chemotherapy medications or undergoing apheresis (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Paediatric population</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The experience in children is limited. A higher frequency of serious adverse reactions in younger children aged 0-5 years (92%) has been observed compared to older children aged 6-11 and</p><p dir="ltr">12-21 years respectively (80% and 67%) and adults. The most common adverse reaction reported was bone pain (see section 5.1 and 5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Reporting of suspected adverse reactions</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local representative.</p><p dir="ltr"><img src="data:image/jpeg;base64,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" alt="" width="583" height="264" vspace="0" hspace="0" border="0" style="width:583px;height:264px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Single doses of 300 mcg/kg have been administered subcutaneously to a limited number of healthy volunteers and patients with non-small cell lung cancer without serious adverse reactions. The adverse events were similar to those in subjects receiving lower doses of pegfilgrastim.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: immunostimulants, colony stimulating factor; ATC Code: L03AA13</p><p dir="ltr">&nbsp;</p><p dir="ltr">Human granulocyte colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Pegfilgrastim is a covalent conjugate of recombinant human G-CSF (r-metHuG-CSF) with a single 20 kd polyethylene glycol (PEG) molecule.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. Similarly to filgrastim, neutrophils produced in response to pegfilgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. As with other haematopoietic growth factors, G-CSF has shown <em>in vitro </em>stimulating properties on human endothelial cells. G-CSF can promote growth of myeloid cells, including malignant cells, <em>in vitro </em>and similar effects may be seen on some non-myeloid cells <em>in vitro</em>.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In two randomised, double-blind, pivotal studies in patients with high-risk stage II-IV breast cancer undergoing myelosuppressive chemotherapy consisting of doxorubicin and docetaxel, use of pegfilgrastim, as a single once per cycle dose, reduced the duration of neutropenia and the incidence of febrile neutropenia similarly to that observed with daily administrations of filgrastim (a median of</p><p dir="ltr">11 daily administrations). In the absence of growth factor support, this regimen has been reported to result in a mean duration of grade 4 neutropenia of 5 to 7 days, and a 30-40% incidence of febrile neutropenia. In one study (n = 157), which used a 6 mg fixed dose of pegfilgrastim the mean duration of grade 4 neutropenia for the pegfilgrastim group was 1.8 days compared with 1.6 days in the filgrastim group (difference 0.23 days, 95% CI -0.15, 0.63). Over the entire study, the rate of febrile neutropenia was 13% of pegfilgrastim-treated patients compared with 20% of filgrastim-treated patients (difference 7%, 95% CI of -19%, 5%). In a second study (n = 310), which used a weight- adjusted dose (100 mcg/kg), the mean duration of grade 4 neutropenia for the pegfilgrastim group was</p><p dir="ltr">1.7 days, compared with 1.8 days in the filgrastim group (difference 0.03 days, 95% CI -0.36, 0.30). The overall rate of febrile neutropenia was 9% of patients treated with pegfilgrastim and 18% of patients treated with filgrastim (difference 9%, 95% CI of -16.8%, -1.1%).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a placebo-controlled, double blind study in patients with breast cancer the effect of pegfilgrastim on the incidence of febrile neutropenia was evaluated following administration of a chemotherapy regimen associated with a febrile neutropenia rate of 10-20% (docetaxel 100 mg/m<sup>2</sup> every 3 weeks for 4 cycles). Nine hundred and twenty eight patients were randomised to receive either a single dose of pegfilgrastim or placebo approximately 24 hours (day 2) after chemotherapy in each cycle. The incidence of febrile neutropenia was lower for patients randomised to receive pegfilgrastim compared with placebo (1% versus 17%, p &lt; 0.001). The incidence of hospitalisations and IV anti-infective use associated with a clinical diagnosis of febrile neutropenia was lower in the pegfilgrastim group compared with placebo (1% versus 14%, p &lt; 0.001; and 2% versus 10%, p &lt; 0.001).</p><p dir="ltr">&nbsp;</p><p dir="ltr">A small (n = 83), Phase II, randomised, double-blind study in patients receiving chemotherapy for <em>de novo </em>acute myeloid leukaemia compared pegfilgrastim (single dose of 6 mg) with filgrastim, administered during induction chemotherapy. Median time to recovery from severe neutropenia was estimated as 22 days in both treatment groups. Long term outcome was not studied (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a phase II (n = 37) multicentre, randomised, open-label study of paediatric sarcoma patients receiving 100 mcg/kg pegfilgrastim following cycle 1 of vincristine, doxorubicin and cyclophosphamide (VAdriaC/IE) chemotherapy, a longer duration of severe neutropenia (neutrophils</p><p dir="ltr">&lt; 0.5 x 10<sup>9</sup>) was observed in younger children aged 0-5 years (8.9 days) compared to older children aged 6-11 years and 12-21 years (6 days and 3.7 days, respectively) and adults. Additionally a higher incidence of febrile neutropenia was observed in younger children aged 0-5 years (75%) compared to older children aged 6-11 years and 12-21 years (70% and 33%, respectively) and adults (see</p><p dir="ltr">sections 4.8 and 5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a phase I (n = 253) randomised, single dose, parallel-group study conducted in healthy subjects the exposure (mean serum concentration-time profiles) of pegfilgrastim delivered by manual injection and by the on-body injector were comparable. The rate (Cmax) and extent (AUC0-inf) of the absorption of pegfilgrastim delivered by the on-body injector were similar to those from the manual injection of the pre-filled syringe. The least-squares geometric mean ratios (90% CIs) (on-body injector to manual injection) were 0.97 (0.83, 1.14) for Cmax and 1.00 (0.84, 1.20) for AUC0-inf within the pre-specified bioequivalence limit of 0.80 to 1.25, and established bioequivalence between the two delivery methods of a single 6 mg dose of pegfilgrastim.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After a single subcutaneous dose of pegfilgrastim, the peak serum concentration of pegfilgrastim occurs at 16 to 120 hours after dosing and serum concentrations of pegfilgrastim are maintained during the period of neutropenia after myelosuppressive chemotherapy. The elimination of pegfilgrastim is non-linear with respect to dose; serum clearance of pegfilgrastim decreases with increasing dose.</p><p>Pegfilgrastim appears to be mainly eliminated by neutrophil mediated clearance, which becomes saturated at higher doses. Consistent with a self-regulating clearance mechanism, the serum concentration of pegfilgrastim declines rapidly at the onset of neutrophil recovery (see figure 1).</p><p>&nbsp;</p><p>Figure 1. Profile of median pegfilgrastim serum concentration and Absolute Neutrophil Count (ANC) in chemotherapy treated patients after a single 6 mg injection</p><p><img alt="" width="579" height="345" src="data:image/jpeg;base64,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" /></p><p><strong>&nbsp;</strong></p><p>Due to the neutrophil-mediated clearance mechanism, the pharmacokinetics of pegfilgrastim is not expected to be affected by renal or hepatic impairment. In an open-label, single dose study (n = 31) various stages of renal impairment, including end-stage renal disease, had no impact on the pharmacokinetics of pegfilgrastim.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>Limited data indicate that the pharmacokinetics of pegfilgrastim in elderly subjects (&gt; 65 years) is similar to that in adults.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The pharmacokinetics of pegfilgrastim were studied in 37 paediatric patients with sarcoma, who received 100 mcg/kg pegfilgrastim after the completion of VAdriaC/IE chemotherapy. The youngest age group (0-5 years) had a higher mean exposure to pegfilgrastim (AUC) (&plusmn; Standard Deviation) (47.9 &plusmn; 22.5 mcg&middot;hr/mL) than older children aged 6-11 years and 12-21 years (22.0 &plusmn; 13.1 mcg&middot;hr/mL and 29.3 &plusmn; 23.2 mcg&middot;hr/mL, respectively) (see section 5.1). With the exception of the youngest age group (0-5 years), the mean AUC in paediatric subjects appeared similar to that for adult patients with</p><p>&nbsp;</p><p>high-risk stage II-IV breast cancer and receiving 100 mcg/kg pegfilgrastim after the completion of doxorubicin/docetaxel (see sections 4.8 and 5.1).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Preclinical data from conventional studies of repeated dose toxicity revealed the expected pharmacological effects including increases in leukocyte count, myeloid hyperplasia in bone marrow, extramedullary haematopoiesis and splenic enlargement.</p><p dir="ltr">&nbsp;</p><p dir="ltr">There were no adverse effects observed in offspring from pregnant rats given pegfilgrastim subcutaneously, but in rabbits pegfilgrastim has been shown to cause embryo/foetal toxicity (embryo loss) at cumulative doses approximately 4 times the recommended human dose, which were not seen when pregnant rabbits were exposed to the recommended human dose. In rat studies, it was shown that pegfilgrastim may cross the placenta. Studies in rats indicated that reproductive performance, fertility, oestrous cycling, days between pairing and coitus, and intrauterine survival were unaffected by pegfilgrastim given subcutaneously. The relevance of these findings for humans is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Sodium acetate*</p><p dir="ltr">Sorbitol (E420)</p><p dir="ltr">Polysorbate 20</p><p dir="ltr">Water for injections</p><p dir="ltr">*Sodium acetate is formed by titrating glacial acetic acid with sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">This medicinal product must not be mixed with other medicinal products, particularly with sodium chloride solutions.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Neulastim &nbsp;may be exposed to room temperature (not above 30&deg;C) for a maximum single period of up to 72 hours. Neulastim &nbsp;left at room temperature for more than 72 hours should be discarded.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The pre-filled syringe for use with the on-body injector may be exposed at room temperature for no longer than 36 hours prior to filling the on-body injector.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not freeze. Accidental exposure to freezing temperatures for a single period of less than 24 hours does not adversely affect the stability of Neulastim .</p><p dir="ltr">&nbsp;</p><p dir="ltr">Keep the container in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pre-filled syringe (Type I glass), with a rubber stopper, stainless steel needle and needle cap with or without an automatic needle guard.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The needle cap of the pre-filled syringe contains dry natural rubber (a derivative of latex) (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">On-body injector, the fluid path is made from polypropylene, cyclic olefin copolymer, silicone rubber and fluorinated ethylene propylene (FEP), with a stainless steel 28 gauge needle. The on-body injector contains three silver oxide batteries and includes an adhesive patch made from non-woven polyester tape single coated with a polyacrylate adhesive.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Each pre-filled syringe for manual administration contains 0.6 mL of solution for injection.</p><p dir="ltr">Each pre-filled syringe for use with the on-body injector contains 0.64 mL of solution for injection. Pack size of one pre-filled syringe, in either blistered or non-blistered packaging.</p><p dir="ltr">Pack size of one pre-filled syringe in blistered packaging co-packed with an on-body injector. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Before use, Neulastim &nbsp;solution should be inspected visually for particulate matter. Only a solution that is clear and colourless should be injected.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The on-body injector must only be used with the Neulastim &nbsp;pre-filled syringe co-packed in the carton. The Neulastim &nbsp;pre-filled syringe for manual administration must not be used with the on-body injector.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Excessive shaking may aggregate pegfilgrastim, rendering it biologically inactive.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When administering using the manual pre-filled syringe, allow the pre-filled syringe to reach room temperature before injecting.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Kyowa Kirin Limited
	Galabank Business Park
	Galashiels
	TD1 1QH
	UK

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>